id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-272419-y3ebt4jm	Monari, Caterina	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review	2020-08-09		.txt	text/plain	6476	318	46	Possible inhibition of SARS-CoV-2 3-chymotrisyn-like (3CL)-protease and papain-like protease Lopinavir is excreted in the gastrointestinal (GI) tract, and thus coronavirus-infected enterocytes might be exposed to higher concentrations of the drug LPV/r tab 200/50 mg: 2 tab BID LPV/r oral sol 80/20 mg: 5 mL BID DRV/cobi tab 800/150 mg: 1 tab QD Gastrointestinal: diarrhea, nausea, vomiting, increased amylase, lipase, total cholesterol and triglycerides (risk factor for pancreatitis) Hepatotoxicity: increasing in GGT, AST, ALT, total bilirubin, hepatitis Cardiological: QT-and PR-interval prolongation, hypertension, bradyarrhytmias; torsade de pointes have been reported in patients treated with LPV/r Metabolical: hyperglycemia and diabetes mellitus, increased uric acid Recently, a randomized, controlled, open-label trial comparing the efficacy of LPV/r versus standard of care was conducted in 199 hospitalized adult patients with severe COVID-19: no significant difference between the two groups neither in the time of clinical improvement (hazard ratio [HR] 1.31; 95% CI 0.95-1.80; p 0.09), nor in the 28-day mortality rate (19.2% versus 25.0%; 95% CI −17.3 to 5.7) was observed [40] .	./cache/cord-272419-y3ebt4jm.txt	./txt/cord-272419-y3ebt4jm.txt